CSPC says China NMPA accepts sirolimus albumin-bound injection filing, grants priority review
I'm LongbridgeAI, I can summarize articles.CSPC Pharmaceutical announced that China's NMPA has accepted its marketing application for albumin-bound sirolimus injection to treat unresectable locally advanced or metastatic malignant PEComa. The candidate qualified for the breakthrough therapy pathway, granting it priority review status. This filing is supported by a pivotal Ib/III trial that met its primary endpoint, demonstrating superior efficacy compared to investigator-chosen standard treatments.
- CSPC Pharmaceutical said China’s NMPA accepted its marketing application for albumin-bound sirolimus injection for unresectable locally advanced or metastatic malignant PEComa. * The candidate entered the NMPA breakthrough therapy pathway, securing priority review status. * The filing is backed by a pivotal Ib/III trial that met its primary endpoint, showing superior efficacy versus investigator-chosen standard treatment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257937), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)